SeqOne Genomics – Somatic

SeqOne bioinformatics platform for NGS data analysis

SeqOne is a bioinformatics platform for NGS data analysis in precision oncology, designed to detect, prioritise and interpret somatic variants and generate actionable clinical reports from raw sequencing data. It helps laboratories and healthcare professionals accelerate the interpretation of NGS data through an end-to-end workflow.

Detailed description

Operating principle

SeqOne Genomics is a genomic data analysis and interpretation platform that covers the entire workflow, from raw NGS data to the generation of clinically actionable information. It integrates advanced bioinformatics algorithms and machine-learning models to detect, prioritise and classify somatic genetic variants. It also includes filtering tools, annotation using premium clinical databases and the automated generation of interpretative reports.

The platform provides an end-to-end solution that includes data transfer, quality control, alignment, variant calling, variant classification, complete report generation and LIMS integration.

SeqOne platform end-to-end workflow

Clinical applications

The software is intended for somatic analysis in oncology, including solid tumours, haematological malignancies and liquid biopsy. In oncology, it provides variant interpretation, treatment recommendations and information about geolocated clinical trials.

The oncology application suite includes the following modules:

SOMAVAR: an application for the advanced bioinformatics analysis of somatic DNA panels. It enables sensitive detection of somatic variants and fusions in targeted gene panels—whether capture- or amplicon-based—with SNV and indel detection at a sensitivity of up to 1% VAF, as well as filtering, prioritisation and classification tools.

SOMAHEMATO: an application specifically designed to detect and interpret key haematological markers, including FLT3-ITD, KMT2A-PTD, IARC annotation of TP53 and fusions. It includes a dedicated module for the reliable determination of IGHV mutational status in chronic lymphocytic leukaemia (CLL).

SeqOne SOMALBX and SOMARNA applications

SOMALBX: a specialised liquid-biopsy (ctDNA) solution designed to maximise the detection of somatic variants in tumour samples without requiring a matched normal sample—a tumour-only workflow. It enables the identification of SNVs, indels, CNVs and fusions or translocations with high sensitivity, down to a VAF of 0.1%. It is intended for early cancer detection, treatment-response monitoring and recurrence surveillance.

SOMARNA: a solution for identifying and visualising fusions from RNA-seq data.

SeqOne SOMACNV CAPTURE application

SOMACNV CAPTURE: designed to detect somatic CNVs (≥300 bp) from capture-panel NGS data. This analysis is always performed after a preliminary analysis in another mode, such as SOMAVAR or SOMAHEMATO.

Somatic variant analysis using SeqOne

Deepmode function: enables dynamic control of the VAF threshold in SOMAVAR and SOMAHEMATO, with manual adjustment between 0.01% and 1%.

SOMAHRD solution for determining HRD status

SOMAHRD: a solution for determining HRD status in solid tumours, validated using data from the PAOLA-1 trial. It combines a gene panel (BRCA1/2) with low-coverage whole-genome sequencing (sWGS) to measure genomic instability (LGA and LPC) and detect amplifications in CCNE1 and RAD51B.

Genomic analysis results generated using SeqOne

Benefits

The platform provides a flexible solution for molecular laboratories that need to interpret complex NGS data within clinically relevant time frames. It delivers robust interpretations through regularly updated databases and automated classification.

It offers the flexibility to adapt panels and workflows to changing clinical requirements, as the tool is compatible with numerous sequencers—including Illumina, MGI and Oxford Nanopore—and reagent kits.

Technology

SeqOne Genomics is cloud-based software that uses artificial intelligence and machine learning to prioritise variants. It integrates annotation databases such as OMIM, COSMIC, CIViC, MolecularMatch and others, together with international guidelines for biological and clinical interpretation, including ACMG, AMP/ASCO and ComPerMed. The platform incorporates regular updates to biological, clinical and therapeutic databases.

Technology and databases integrated into the SeqOne platform

Intended users

The product is intended for molecular laboratories performing NGS analyses, as well as biologists, pathologists, clinicians and oncologists. It is also intended for biotechnology organisations and other entities interested in advanced genomic analysis.

Security, compliance and support

The SeqOne platform is certified as a Class C CE-IVD in vitro diagnostic medical device under the IVDR. The company is ISO 13485 certified as a medical-device manufacturer and holds ISO 27001, HDS and GDPR certifications for information security and healthcare-data hosting, ensuring secure information management and data protection.

Key features

CE-IVDR bioinformatics platform for somatic NGS analysis in precision oncology. End-to-end analysis from raw genomic data to actionable clinical reports. Dedicated applications for somatic panels in solid tumours, haemato-oncology—from DNA and RNA—and ctDNA liquid biopsy. Detection of SNVs, indels, CNVs, fusions, translocations and other relevant genomic events. Variant prioritisation and classification using artificial intelligence and machine learning. Integration of annotation databases and international interpretation guidelines. LIMS integration and automation of data upload, analysis, quality control and exports.

Area:

Oncohematology, Software, Software, Somatic Analysis Solutions

Brand:

Consult our experts

Google reCaptcha: Invalid site key.

Related products

SureSelect Cancer CGP Assay

Targeted-enrichment NGS pan-cancer panel for comprehensive genomic profiling (CGP) of solid tumours. Designed to detect somatic variants at DNA level (SNVs, indels, CNVs, translocations) and RNA level (gene fusions), as well as to assess complex immuno-oncology biomarkers such as tumour mutational burden (TMB), microsatellite instability (MSI) and homologous recombination deficiency (HRD). Detailed Description Operating principle…
Agilent
Next Generation Sequencing (NGS)

SeqOne HRD Solution con Agilent SureSelect CD HRR17 Panel

HRD analysis solution combining low-coverage whole-genome sequencing (shallow/low-pass WGS) and a targeted gene panel to detect genomic instability, BRCA1/2 alterations and other genes related to homologous recombination. It is designed for laboratories wishing to implement HRD testing in-house with an automated, efficient and clinically validated workflow. Detailed Description SeqOne’s HRD solution combines shallow WGS and…
Agilent
Next Generation Sequencing (NGS)

OncoSELECT®

Comprehensive targeted liquid biopsy assay designed to support decision-making in oncology through the analysis of 74 clinically relevant genes. The solution encompasses everything from library preparation reagents to bioinformatics analysis, clinical interpretation and the generation of detailed reports. 3.- Detailed Description Operating principle OncoSELECT® is an advanced liquid biopsy panel based on circulating cell-free DNA…
OncoDNA
Next Generation Sequencing (NGS)

Agilent SureSelect Human All Exon V8.

High-performance exome for the enrichment of human coding regions, with updated coverage of RefSeq, CCDS and GENCODE, including the TERT promoter and difficult-to-capture exons. 3.- Detailed Description Operating principle SureSelect Human All Exon V8 is based on NGS library preparation and capture enrichment of target regions of the human exome. The workflow is compatible with…
Agilent
Next Generation Sequencing (NGS)